Protalix Biotherapeutics Inc V.PLX.H

Primary Symbol: PLX

Healthcare Biotechnology

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.

NYSEAM:PLX - Post by User

Protalix Biotherapeutics Inc > Keep the good news coming

<< Previous

Bullboard Posts

Next >>

Comment by Theconsortmanon Sep 05, 2019 6:19pm

194 Views

Post# 30100202

RE:RE:RE:Keep the good news coming

They had to farm out because they have no capital and desperately need cash flow. This well should help do that but they are not going to find a lineup of willing acquirers to get into bed with a murky off shore company. PLX has the yoke around their necks of legacy gassy production and it will be a tough struggle. Altura who is the leader in this Rex play is also suffering but not as bad as they don't have the drag of the marginal gassy assets. PLX did strike out on the other mid Mannville play (Sparky) that Blackspur is developing to the NW. It is unfortunate that that drill did not work out.

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security